SAB-176 is an antiinfluenza human immunoglobulin (IgG) immunotherapy. The fully human polyclonal antibody targets four influenza virus strains and mimics the body's natural way to fight disease. SAB-176 has the ability to adapt to future emerging and mutating seasonal strains, one of the urgent limitations of existing seasonal influenza treatments.

SAB-176 was generated using the company's proprietary DiversitAb platform and is designed to specifically bind to type A and type B influenza viruses. Preclinical testing has demonstrated that the drug has high potency and neutralization against various influenza strains.

The phase I trial is a randomized, double-blind, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of the drug as delivered to 27 healthy patients. The phase I study is expected to be completed in early 2021. The study will inform dosage for a phase II trial.